Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Poster Schedule
Home
Poster Schedule
All Days
Tue, May 14
Wed, May 15
Poster Schedule
Type here to filter the list
Wednesday, May 15, 2024
10:30 AM – 11:30 AM
PT
(W1030-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides III Thermodynamic Analysis on Higher-Order Structure of Oligonucleotides
Favorite
10:30 AM – 11:30 AM
PT
(W1030-01-02) Potential Biomedical Applications of Silver Nanoparticles Synthesized Using Anisotes trisulcus Extract from Saudi Arabia: Antioxidant, Antibacterial, and Anti-Proliferative Properties
Favorite
10:30 AM – 11:30 AM
PT
(W1030-01-03) Oral Delivery of Remdesivir Analogues: Alternatives for Intravenous Remdesivir with Reduced Potential Drug-Drug Interactions
Favorite
10:30 AM – 11:30 AM
PT
(W1030-01-04) Preparation and Scale-Up of Liposomal Amphotericin B Formulation and a Comparison with Commercially Available Counterpart, Ambisome®
Favorite
10:30 AM – 11:30 AM
PT
(W1030-02-06) Antibody Synthesis in Cell-Free for High-Throughput Production and Screening
Favorite
10:30 AM – 11:30 AM
PT
(W1030-02-07) Comparative Analyses of Thermal Stability Amplifying Peptide Dendrons and Polysorbates
Favorite
10:30 AM – 11:30 AM
PT
(W1030-02-08) Optimization of Artificial Colonic Mucus for Drug Diffusion Study
Favorite
10:30 AM – 11:30 AM
PT
(W1030-02-09) Design and Evaluation of a Cyclic Peptide-Epirubicin Conjugate to Enhance Anticancer Activity and Reduce Cardiac Toxicity
Favorite
10:30 AM – 11:30 AM
PT
(W1030-02-10) Delivery of Carbonic Anhydrase 9 siRNA by Lipid Nanoparticles
Favorite
10:30 AM – 11:30 AM
PT
(W1030-02-11) Machine Learning Approaches to Analysis of Microscopy Images of Polysorbate Degradation Product Particles
Favorite
11:30 AM – 12:30 PM
PT
(W1130-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (2) Oxidation
Favorite
11:30 AM – 12:30 PM
PT
(W1130-02-07) Biodistribution Study of a Bivalent SARS-CoV-2 mRNA Vaccine in Rat
Favorite
11:30 AM – 12:30 PM
PT
(W1130-02-08) Oral Absorption of Semaglutide: Pharmacokinetic Modeling and Molecular Dynamics Simulations
Favorite
11:30 AM – 12:30 PM
PT
(W1130-02-09) Immunogenicity Risk Assessment of Salmon Calcitonin Peptide Impurities Using In Silico and In Vitro Methods
Favorite
11:30 AM – 12:30 PM
PT
(W1130-02-10) Choosing the Right Bioanalytical Platform to Accommodate a Biotherapeutic Pharmacokinetic Measurement in Serum and CSF: A Case Study
Favorite
11:30 AM – 12:30 PM
PT
(W1130-02-11) Comparison of a Microfluidic Generic Total Antibody (TAb) Assay with Independent Neutralizing Antibody (NAb) and TAb Assays for the Detection of Pre-existing Antibodies against AAV Vectors
Favorite
12:30 PM – 1:30 PM
PT
(W1230-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides IV Evaluation of Compactness of Oligonucleotides for Determining Their Higher-Order Structure
Favorite
12:30 PM – 1:30 PM
PT
(W1230-01-02) Impact of Amino Acids as Excipients in Biologic Drug Products Formulation Development
Favorite
12:30 PM – 1:30 PM
PT
(W1230-01-05) Development of a Marburg Self-amplifying mRNA-Lipid Nanoparticle Vaccine: Differential Effects When Co-formulated with Toll Receptor Agonists
Favorite
12:30 PM – 1:30 PM
PT
(W1230-02-06) Strategies for the Development and Characterization of Sensitive Anti-oligonucleotide Antibodies for Application in Anti-drug Antibody Assays
Favorite
12:30 PM – 1:30 PM
PT
(W1230-02-07) Docetaxel and QDs Based Nano Lipidic Theragnostic System for Cure and Real-Time Monitoring of Breast Cancer: Efficacy and Safety Studies in Rats
Favorite
12:30 PM – 1:30 PM
PT
(W1230-02-09) LC-MS FFPE Tissue Analysis Across Multiple Murine Tissues Supports Mouse Relevance for On-Target/Off-Tumor Toxicity Assessment for Anti-STEAP2 CAR-T Therapeutic Development
Favorite
12:30 PM – 1:30 PM
PT
(W1230-02-10) Qualification of a 48-plex Cytokine Olink Panel to Support Rare Disease and Pediatric Clinical Studies
Favorite
12:30 PM – 1:30 PM
PT
(W1230-02-11) Comprehensive Assessment of Immunogenicity Risk of Host Cell Proteins in Biologics and Vaccines Using In Silico and In Vitro Methods
Favorite
12:30 PM – 1:30 PM
PT
(W1230-01-03) Elastin-Like Polypeptide (ELP) Antibody Fusions Targeting IL-6: Pharmacology and Pharmacokinetics
Favorite
1:30 PM – 2:30 PM
PT
(W1330-01-01) Stabilization of Viruses for Vaccines and Gene Therapy by Spray Drying and Lyophilization
Favorite
1:30 PM – 2:30 PM
PT
(W1330-01-02) Poloxamer 188 and Propylene Glycol Loaded with Novel Pyridine-Based 1,2,4-Triazolo-Tethered Indole Conjugate as Rectal Suppository to Treat Colorectal Cancer
Favorite
1:30 PM – 2:30 PM
PT
(W1330-01-03) Deciphering the Role of Hydrogel Network Topology in Programmably Degradable Hydrogels
Favorite
1:30 PM – 2:30 PM
PT
(W1330-01-04) Prolonged Ocular Delivery of Sunitinib from Poly (diol-tricarballylate) Injectable Biodegradable Elastomeric Tiny Implant for Diabetic Retinopathy Treatment
Favorite
1:30 PM – 2:30 PM
PT
(W1330-01-05) Extrapolating the Use of Microfluidic Chips to Formulate Reproducible and Effective Nanoemulsions for Subunit Vaccines: A Paradigm Shift in Manufacturing Emulsion Adjuvants
Favorite
1:30 PM – 2:30 PM
PT
(W1330-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (1) Deamidation
Favorite
1:30 PM – 2:30 PM
PT
(W1330-02-09) Using Cryo-TEM to Characterize Structural Details of LNPs during Manufacturing
Favorite
1:30 PM – 2:30 PM
PT
(W1330-02-10) Next-Generation Biocompatible HPLC System for Enhanced Analysis of Biotherapeutics
Favorite
1:30 PM – 2:30 PM
PT
(W1330-02-11) One Drop of Blood, Multiple Sets of Data --- Establishing A Common Protocol for Serotype Specific IGG Concentration Testing Using Mitra® VAMS Dry Blood Samples to Support Vaccine Clinical Studies
Favorite
1:30 PM – 2:30 PM
PT
(W1330-02-07) Enhancing Antibody Detection for PABAD-Based Neutralizing Antibody Detection and Validation
Favorite
2:30 PM – 3:30 PM
PT
(W1430-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides V Biological Function Analysis of Oligodeoxynucleotides
Favorite
2:30 PM – 3:30 PM
PT
(W1430-01-02) High Concentration Protein Suspensions: A Case Study for Subcutaneous Delivery of Bevacizumab
Favorite
2:30 PM – 3:30 PM
PT
(W1430-01-04) Innovative Device for Concomitant Therapeutic Compound Delivery into the Brain and Neural Recordings - Feasibility Bench and In Vivo Studies
Favorite
2:30 PM – 3:30 PM
PT
(W1430-01-05) Characterization of Protein Antigens in Liposomal Vaccines Using Differential Scanning Fluorimetry
Favorite
2:30 PM – 3:30 PM
PT
(W1430-02-06) Application of a Novel Affinity Purified Chicken IgY in an Immunoaffinity LC-MS/MS Assay for Rapid Quantitation of Monoclonal Antibody Therapeutics and ADCs in Nonclinical Species
Favorite
2:30 PM – 3:30 PM
PT
(W1430-02-07) Novel Use of Recombinant Dimeric IgA Monoclonal Antibodies as Cyst-Targeted Therapeutics in Polycystic Kidney Disease
Favorite
2:30 PM – 3:30 PM
PT
(W1430-02-08) In Vitro Method Using Circulating Tumor Cells-Derived Organoids from Patients with Solid Tumors to Transform Oncology Drug Development
Favorite
2:30 PM – 3:30 PM
PT
(W1430-02-09) Exploring the Future Potentials of High-Resolution Mass Spectrometry for Regulated Bioanalysis
Favorite
2:30 PM – 3:30 PM
PT
(W1430-02-10) Analysis of Anti-Drug Antibodies (ADA) in Multiple Animal Species from mRNA LNP Therapeutics Supporting Rare Diseases Demonstrated Low Immunogenicity of PEG-2000 by ECLA and ELISA Methodology
Favorite
3:30 PM – 4:30 PM
PT
(W1530-02-06) Age-Dependent Reduction in Hepatic Vector Genome Loss in Juvenile OTC
spf-ash
Mice Following a Single Dose of DTX301 and Partial Compensation Achieved with a Higher Dose
Favorite
3:30 PM – 4:30 PM
PT
(W1530-02-08) Non-invasive Molecular Imaging of V3 Receptors to Localize ACTH-Dependent Cushing's Syndrome and Precision Surgery of Corticotropinoma
Favorite
3:30 PM – 4:30 PM
PT
(W1530-02-09) Development of Non-Cell Based Potency Assays for Bispecific Antibodies
Favorite
3:30 PM – 4:30 PM
PT
(W1530-02-10) An “I” (Immunogenicity Risk Assessment) for an Eye (Ophthalmology Biologics)
Favorite
3:30 PM – 4:30 PM
PT
(W1530-02-11) Evaluation of API 7500 Integrated System with Microflow LC System M5 Using Sulfamethazine (SDX) Neat Solution
Favorite
